

Cancer Genetics inks supply contract with Agilent

26 September 2018 | News

Probes for CGI's FISH-based HPV-Associated Cancer Test (FHACT) test to be manufactured by Agilent



Singapore - Cancer Genetics, a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, announced that it has signed a non-exclusive supply agreement with Agilent Technologies through which Agilent will manufacture Cancer Genetics' proprietary FISH probe reagents.

Under the terms of the agreement, Agilent will manufacture and supply Cancer Genetics with the custom probe for use in the Company's FISH-based HPV-Associated Cancer Test (FHACT). Additionally, Cancer Genetics' plans to outlicense the probes through domestic and international distribution channels, with such licensors having the ability to purchase probes manufactured by Agilent.

John A. Roberts, Chief Executive Officer of Cancer Genetics, commented, "We are pleased to finalize our agreement with Agilent, who has established itself as a leader in delivering solutions for scientific research, especially in manufacturing of FISH probes. This agreement marks an important milestone for Cancer Genetics and the company's FHACT test as it allows for expansion of our international business opportunities by outlicensing our probes, which is an integral part of the company's new strategy for revenue generation and path to profitability."

Cancer Genetics' FHACT is the only four color FISH probe available for cervical cancer testing. When used as an additional triage before colposcopy, FHACT can help identify women with low-grade or undetermined lesions (ASCUS/LSIL) who are likely to progress to more advanced cervical disease. FHACT can help reduce healthcare costs, relieve patient anxiety, and prevent complications associated with over treatment by reducing the number of unnecessary colposcopies performed.